Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625229 | 0.89 | EPHX2 (0.39) | EPHX2PIK3R1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL4776859 | 0.88 | PIK3R1 (0.45) | EPHX2PIK3R1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL5567244 | 0.86 | HDAC2 (0.39) | EPHX2PIK3R1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL1003106 | 0.81 | EPHX2 (0.46) | EPHX2USP2SMN1; SMN2ADAM17 | |
| SCHEMBL29205778 | 0.80 | USP2 (0.45) | EPHX2USP2SMN1; SMN2ADAM17 | |
| SCHEMBL27139196 | 0.80 | OPRD1 (0.43) | SMN1; SMN2USP30 | |
| SCHEMBL18319088 | 0.79 | EPHX2 (0.42) | EPHX2USP2SMN1; SMN2ADAM17 | |
| SCHEMBL1586974 | 0.77 | EPHX2 (0.43) | EPHX2USP2SMN1; SMN2ADAM17HDAC2 | |
| SCHEMBL4727152 | 0.76 | SCD5 (0.45) | PIK3R1PIK3CAPIK3CDPIK3CBUSP30 | |
| SCHEMBL18342437 | 0.76 | USP2 (0.42) | EPHX2USP2SMN1; SMN2USP30SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | EPHX2 1543/4885PIK3R1 1643/4885PIK3CA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.